The correlation between PRMT5 levels, as a DDR‐related gene, and the response to first‐line DNA‐damaging chemotherapeutic agents, including CPT‐11, oxaliplatin, and 5‐fluorouracil, in patients with CRC was further analyzed. Here, PRMT5 is linked to colorectal carcinoma.